Navigation Links
K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
Date:7/15/2010

ain assets, and the terms of such transactions;
  • the possibility that default on one type or class of the Company's indebtedness could result in cross default under, and the acceleration of, its other indebtedness;
  • the risks that present or future changes in the Board of Directors or management may lead to an acceleration of the Company's bonds or to adverse actions by government agencies or our auditors;
  • if a director of our company, or a shareholder with an ownership interest in our company of 5% or more, is excluded from participating in federal or state health care programs, then HHS may use its discretionary authority to also exclude our company from participation in federal healthcare programs;
  • the risk that the failure to comply with the quantitative listing standards of the New York Stock Exchange, including with respect to minimum share price and public float, could result in delisting of our shares on the New York Stock Exchange, which would harm the market price of the Company's Class A common stock and Class B common stock;
  • the risk that the Company will be unable to engage a successor independent registered public accounting firm promptly or be unable to complete the review of its Annual Report on Form 10-K for its fiscal year ended March 31, 2010 promptly, which would impact the Company's compliance with New York Stock Exchange listing standards, and the Securities Exchange Act of 1934, as amended;
  • delays in retaining successor auditors; and
  • the risks detailed from time-to-time in the Company's filings with the SEC.

  • This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's forward-looking statements.

    Because the factors referred to above, as well as the statements included elsewhere in this press release, could cause actual results or outcom
    '/>"/>

    SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)... 1, 2014 The global high content screening ... the ,Threat of Obsolescence, wherein technologies as well as ... and biotechnology companies as well as academic and government ... as a powerful research tool in drug discovery. The ... in the high content screening market. In high content ...
    (Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, Inc. ... patented and proprietary technology used to develop and ... bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today ... from Abengoa Bioenergy for commercial scale production of ... into ethanol, developed under Abengoa,s license agreement with ...
    (Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014 /PRNewswire/ ... cell-free molecular diagnostics, announced today that Eli ... Sloan Kettering Cancer Center (MSK), presented clinical data ... Trovagene,s precision cancer monitoring platform for the determination ... from a liquid biopsy.  The results were presented ...
    Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
    (Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
    (Date:10/1/2014)... published today in the Journal of the American ... 50 years with moderate or severe chronic knee pain, ... the University of Melbourne randomly assigned 282 patients (50 ... acupuncture or sham or pretend laser treatment. , ... acupuncturists blinded to laser and sham (inactive) laser acupuncture. ...
    (Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
    (Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
    (Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
    Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2
    ... ... product development. , ... Toronto, ON (Vocus) March 29, 2010 -- Therapure Biopharma Inc. today announced a fill/finish ... Under the terms of the agreement, Therapure will provide custom fill/finish services for a ...
    ... ... nonprofit organization that engages hundreds of thousands of students into humanitarian ... collaborative management of tasks and workflow. Absolute’s Chief Operating Officer reports ... operations transparency, thanks to Wrike’s unique project collaboration features. , ...
    ... enrolled in therapeutic clinical research trials shows that they don,t ... participation, nor do they feel they are genuinely involved in ... Yoram Unguru, M.D., an associate faculty member at the Johns ... 29 in the journal Pediatrics . While an ...
    ... combination destroys precancerous colon polyps with no effect on normal ... cancer, a team of scientists at The University of Texas ... edition of the journal Nature . The regimen, ... cancer tissue in the lab, appears to address a problem ...
    ... rats, the more fattening foods they ate, the more they wanted ... they,d like to eat less but feel almost powerless to stop ... too true. , The theory stems from a study in rats. ... of bacon, pound cake, candy bars and other junk food, the ...
    ... Unethical job ... wage jobs in Canada. Sometimes these carers do not even have a job when they ... one Vancouver-based business owner says problems could persist. , ... (PRWEB) March 28, 2010 -- New federal legislation coming into force ...
    Cached Medicine News:Health News:Therapure Biopharma Inc. signs fill/finish contract with Kane Biotech Inc. 2Health News:COO Becomes 75% More Effective in Tracking Delegated Tasks 2Health News:COO Becomes 75% More Effective in Tracking Delegated Tasks 3Health News:Childhood cancer patients enrolled in clinical trials need clearer communication about their role 2Health News:Childhood cancer patients enrolled in clinical trials need clearer communication about their role 3Health News:Paired drugs kill precancerous colon polyps, spare normal tissue 2Health News:Paired drugs kill precancerous colon polyps, spare normal tissue 3Health News:Junk Food 'Addiction' May Be Real 2Health News:Junk Food 'Addiction' May Be Real 3Health News:Exploitation of Overseas Nannies and Caregivers Could Continue Despite New Canadian Immigration Laws 2Health News:Exploitation of Overseas Nannies and Caregivers Could Continue Despite New Canadian Immigration Laws 3
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: